The JOURNAL OF CLINICAL PSYCHIATRY is a premier publication dedicated to advancing the understanding and treatment of psychiatric disorders. Established in 1978 and published by Physicians Postgraduate Press, this esteemed journal provides a vital platform for researchers, clinicians, and mental health professionals to share innovative findings and evidence-based practices in psychiatry. With an impressive impact factor and recognized as a Q1 journal in both Medicine (miscellaneous) and Psychiatry and Mental Health, the journal ranks among the top in its field, sitting at 96th out of 567 in Scopus rankings, placing it in the 83rd percentile. The journal's commitment to high-quality, peer-reviewed articles facilitates the dissemination of knowledge crucial for advancing clinical practices and improving patient outcomes. Access to its latest research is offered through institutional subscriptions, making it an essential resource for anyone involved in the mental health sector, from seasoned practitioners to aspiring students.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

Journal of Psychiatric Practice, published by Lippincott Williams & Wilkins, is a premier journal dedicated to advancing the field of psychiatry and mental health. With a focus on evidence-based clinical practice, the journal has been a respected resource since its inception, providing a platform for a wide range of articles, including original research, reviews, and case reports from 1997 to the present. As of 2023, it holds a Q3 ranking in Psychiatry and Mental Health, reflecting its influential role in the academic community. The Journal is aimed at researchers, mental health professionals, and students, promoting the dissemination of essential knowledge and innovative practices. Subscribers benefit from the latest findings and discussions in the field while contributing to the ongoing advancements in psychiatric care. Although not classified as open access, the journal ensures wide accessibility to its valuable content, further solidifying its commitment to the mental health discipline.

HARVARD REVIEW OF PSYCHIATRY is a prestigious academic journal focused on the field of psychiatry and mental health, published by Lippincott Williams & Wilkins. Established in 1993, this journal has become a critical resource for researchers, clinicians, and students alike, providing cutting-edge insights and scholarly articles that address contemporary issues in mental health. With an impressive impact factor reflected in its Q1 ranking in Psychiatry and Mental Health, the journal ranks #90 out of 567 in its category in Scopus, placing it in the top 16% of publications in this field. The journal is dedicated to disseminating high-quality research and fostering dialogue among professionals, thus contributing significantly to the advancement of psychiatric sciences. Researchers can access the journal through traditional subscriptions, ensuring that vital knowledge and innovative practices are shared among a global audience.

EUROPEAN NEUROPSYCHOPHARMACOLOGY, published by Elsevier, is a prestigious academic journal that serves as a cornerstone in the field of neuropsychopharmacology, embracing multidisciplinary research at the intersection of neuroscience, psychiatry, and pharmacology. Since its establishment in 1990, this journal has consistently delivered cutting-edge research and reviews that drive forward our understanding of central nervous system disorders and their treatment. With an impressive impact factor and ranked in the Q1 category for several disciplines, including Biological Psychiatry and Neurology, it attracts submissions from leading researchers globally. The journal’s Scopus rankings reflect its significant influence, ranking in the top echelons across various categories such as Medicine and Neuroscience. While the journal maintains subscription access, readers are encouraged to explore the breadth of important findings that contribute to advancements in treatment options and improve patient care. EUROPEAN NEUROPSYCHOPHARMACOLOGY not only supports the dissemination of pivotal research but also fosters collaboration and dialogue within the scientific community, making it an essential resource for researchers, clinicians, and students dedicated to the complexities of brain health.

The Journal of Neurology, published by Springer Heidelberg, stands as a distinguished platform within the realm of neurology, encompassing both fundamental and clinical aspects of the field. With an impressive impact factor and notable rankings—43rd out of 400 in clinical neurology and 22nd out of 192 in neuroscience—this journal consistently showcases high-quality research and groundbreaking studies. Established in 1974, it has evolved over nearly half a century to adapt to the latest advancements, maintaining its Q1 quartile ranking for both neurology and clinical neurology in 2023. With an extensive scope that includes original research, reviews, and case reports, the journal fosters knowledge dissemination and engages a global audience of researchers, clinicians, and students. Although it does not currently offer open access options, its rigorous peer-reviewed publication process ensures that only the most impactful studies contribute to the understanding and advancement of neurological sciences.

The American Journal of Psychiatry, published by the renowned American Psychiatric Publishing, Inc., stands as a premier platform in the field of Psychiatry and Mental Health. With its inaugural edition released in 1945, this esteemed journal has consistently provided a wealth of knowledge, shaping the landscape of psychiatric research and practice globally. Notably, in the latest 2023 Scopus rankings, it achieved an impressive rank of #7 out of 567 journals in its category, placing it in the top 2% percentile, indicative of its substantial impact within the field. The journal is committed to publishing high-quality, peer-reviewed original research, clinical studies, and reviews that advance psychiatric knowledge and treatment options. Although it does not currently offer open access, its contributions are vital for researchers, clinicians, and students dedicated to improving mental health care and understanding complex mental health disorders. As an essential resource, it continues to foster scholarly communication among professionals who are at the forefront of psychiatric science.

Middle East Current Psychiatry (MECPsych), published by SpringerNature, is a prominent open-access journal dedicated to advancing the field of psychiatry and mental health in the Middle East and beyond. Since its establishment in 2011, MECPsych has aimed to disseminate high-quality research, reviews, and reports that capture recent developments in psychiatric science, clinical practice, and public health considerations in mental well-being. With an impact factor reflective of its growing influence and classified in the Q3 quartile for Psychiatry and Mental Health, the journal offers invaluable insights backed by rigorous peer review processes. Operating under an open access model since 2019, MECPsych ensures that its articles are freely accessible to a global readership, enhancing the visibility and application of research findings. As part of its ongoing commitment to enriching understanding in the field, MECPsych also encourages submissions that explore the unique cultural, societal, and economic factors influencing mental health across the region. This approach not only supports researchers, professionals, and students in their pursuit of knowledge but also fosters a collaborative dialogue among mental health stakeholders in the Middle East and around the world.

NORDIC JOURNAL OF PSYCHIATRY is a pivotal publication in the field of psychiatry and mental health, dedicated to advancing knowledge and fostering dialogue among researchers, clinicians, and students. Published by Taylor & Francis Ltd, this esteemed journal, with an ISSN of 0803-9488 and E-ISSN 1502-4725, serves as a platform for innovative research and critical reviews that address crucial mental health issues affecting Nordic populations and beyond. Its impact is underscored by a notable Q2 ranking in the Psychiatry and Mental Health category for 2023, along with a respectable position within the Scopus ranking at #268 out of 567. The journal has been a reliable source of scientific inquiry since its inception in 1947, and it aims to facilitate significant advancements in the understanding and treatment of psychiatric disorders. By providing access to high-quality research without open access options, NORDIC JOURNAL OF PSYCHIATRY remains a must-read for those dedicated to progressing mental health science in a global context.

Psychiatry Investigation is a prominent, peer-reviewed journal published by the Korean Neuropsychiatric Association, focusing on advancements in the fields of psychiatry and mental health. With an ISSN of 1738-3684 and an E-ISSN of 1976-3026, this journal has steadily gained recognition within the academic community since its inception in 2006. Spanning a dynamic spectrum of research topics, it aims to disseminate innovative findings and facilitate discussions that contribute to the understanding and treatment of psychiatric disorders. As evidenced by its current Scopus rankings—positioned in the Q2 category for Psychiatry and Mental Health and the Q3 category for Biological Psychiatry—the journal is committed to maintaining high scholarly standards and impactful research contributions. Although fully open access is not available, the relevance of its content ensures that it remains a critical resource for researchers, clinicians, and students alike, furthering knowledge and practices in the field of mental health.